Citius Pharmaceuticals, Inc. Pitch Deck: All 40 Slides

Citius Pharmaceuticals (CTXR) utilizes this 2018 corporate presentation to position itself as a solution to a specific, high-cost medical problem: infected central venous catheters (CVCs). The deck highlights their lead product, Mino-Lok, which aims to salvage infected catheters rather than the current standard of 'remove and replace.' By showcasing Phase 2b results where the Mino-Lok arm achieved a 0% overall complication rate compared to 18% in the control arm (Slide 17), the company builds a clinical argument for efficacy. The strategy relies on targeting indications with few competitors a…

Key takeaways

• The company targets drug candidates with a low-risk development horizon of 3-4 years (Slide 5).
• Mino-Lok is positioned as a treatment for infected central venous lines, claiming no other products are currently being developed for this specific treatment indication (Slide 25).
• Phase 2b trial results for Mino-Lok showed a 0% overall complication rate across 30 patients, versus an 18% rate in the 60-patient control arm (Slide 17).
• The current standard of care for catheter-related bloodstream infections is 'remove and replace,' which the deck characterizes as risky and costly (Slide 13).
• Citius highlights a secondary candidate, CITI-001, which showed a 69.60% improvement in global severity at Day 15 in Phase 2a trials (Slide 29).
• The management team features significant industry experience, including a CEO who was the former President of Roche Laboratories (Slide 33).
• The deck emphasizes intellectual property protection for at least 10 years as a core strategic objective (Slide 5).
• Competitive analysis identifies CorMedix's Neutrolin as a preventive-only competitor, lacking the treatment capabilities of Mino-Lok (Slide 25).

Frequently asked questions

What is the primary medical problem Citius is trying to solve?

Citius focuses on Biofilm formation in central venous catheters (CVCs). As shown on Slide 9, pathogens attach to the catheter surface and form colonies that exude a fibrous glycocalyx, protecting them from standard antibiotics. Currently, doctors must remove and replace these catheters, which is a costly and invasive procedure. Citius proposes Mino-Lok as a way to treat the infection and salvage the existing catheter.

How does Citius differentiate itself from competitors like CorMedix?

According to Slide 25, Citius claims there are no other products currently being developed for the *treatment* of infected central venous lines. They identify CorMedix’s Neutrolin as a competitor, but note it is for 'Prevention only' and used in prophylaxis. Citius asserts that no company currently has U.S. regulatory approval for a lock solution that treats and salvages infected CVCs.

What were the key findings of the Mino-Lok Phase 2b trial?

Slide 17 details the Phase 2b results comparing 30 Mino-Lok patients to 60 control patients. The Mino-Lok arm reported 0% complications and 0% relapses. In contrast, the control arm (the standard 'remove and replace' method) saw an 18% overall complication rate, including 3 relapses and 8 general complications. Both arms achieved 100% microbiologic eradication initially.

Who is leading Citius Pharmaceuticals?

The leadership team is highly experienced in the pharmaceutical sector. CEO Myron Holubiak is the former President of Roche Laboratories, where he transformed the company into an antibiotic and biotech leader. Chairman Leonard Mazur has founded several pharmaceutical companies, including Triax and Akrimax. The board also includes former executives from Johnson & Johnson and medical directors (Slides 33 and 37).

What are the primary goals for the Mino-Lok Phase 3 trial?

As outlined on Slide 21, the primary outcome measure is the proportion of subjects successfully treated at the 8-week mark. Success is defined by three criteria: eradication of the pathogen, stabilization or improvement of infection signs/symptoms, and catheter salvage. Secondary measures include all-cause mortality at 14 and 28 days and the overall safety profile of the treatment.

Citius Pharmaceuticals, Inc. (CTXR) pitch deck: the facts

Company

Citius Pharmaceuticals, Inc. (CTXR)

Year

2018

Stage

Clinical Stage (Phase 2b/Phase 3)

Slides

40

Sector

Pharmaceuticals / Biotech

Deck type

Corporate Presentation / Investor Deck

Outcome

Publicly Traded (NASDAQ)

Headquarters

Cranford, New Jersey, USA

Citius Pharmaceuticals, Inc. (CTXR) pitch deck PDF

The full Citius Pharmaceuticals, Inc. (CTXR) deck is embedded on this page and can be read slide by slide in the browser — no download or account required. Each slide is covered in the breakdown above.

What the Citius Pharmaceuticals, Inc. pitch deck was used for

This deck is a ~40‑slide investor presentation for Citius Pharmaceuticals (NASDAQ: CTXR), a clinical‑stage biopharmaceutical company, dated around 2018–2019 when the company described itself as a clinical / late‑stage specialty pharma focused on critical care anti‑infective products. The presentation centers on its lead asset **Mino-Lok**, an antibiotic lock solution being advanced from Phase 2b into a pivotal Phase 3 trial for catheter‑related bloodstream infections, and also references pipeline assets such as Halo‑Lido and Mino‑Wrap. In parallel with this deck, Citius was a publicly listed company using follow‑on equity offerings to fund its Phase 3 Mino-Lok program and other pipeline activities, rather than a traditional private venture round.

Business model: Specialty / late-stage biopharmaceutical company developing and commercializing critical care and anti‑infective products, primarily for hospital and specialty care settings.

Year

2019

Founded

2007

Round: Follow‑on underwritten public offering by an already‑public, clinical‑stage biopharmaceutical company (not a traditional private venture round).

Raised: $7.0 million gross proceeds; approximately $6.1 million net proceeds after underwriting discounts, commissions, and offering expenses in an underwritten public offering of common stock and warrants that closed on September 27, 2019.

Headquarters: Cranford, New Jersey, United States (principal executive offices at 11 Commerce Drive, First Floor, Cranford, NJ 07016 in more recent filings and profiles).

Industry: Biopharmaceuticals / Pharmaceuticals (critical care, anti‑infectives, oncology supportive care).

Use of funds as presented: Citius stated it intended to use the net proceeds for general corporate purposes, including funding its Phase 3 clinical Mino-Lok trial for the treatment of catheter‑related bloodstream infections, advancing the IND regulatory pathway for Mino-Wrap, supporting its Phase 2b clinical trial of Halo-Lido cream for the treatment of hemorrhoids, and for working capital and capital expenditures.

What happened after the Citius Pharmaceuticals, Inc. deck

Following this 2018–2019 investor deck, Citius continued to develop its lead asset Mino-Lok through a pivotal Phase 3 trial for catheter‑related bloodstream infections, streamlined the trial design through endpoint and sample‑size modifications to reduce cost and duration, and financed operations and clinical programs via public equity offerings, including a $7.0 million underwritten offering in S

• Citius advanced Mino-Lok into a pivotal Phase 3 trial for catheter‑related bloodstream infections under an FDA‑cleared p
• By November 2019, Citius reported a modification to the primary endpoint of the Mino-Lok Phase 3 trial that substantiall
• The company completed a Phase 2b clinical trial for its hemorrhoid treatment candidate Halo‑Lido (CITI‑002), as reflecte
• Citius evolved from a Massachusetts‑based entity (Maynard, MA) into a Cranford, New Jersey‑headquartered public biopharm

What the Citius Pharmaceuticals, Inc. deck got right

• Differentiated lead asset focused on catheter salvage in serious infections. The company’s lead candidate **Mino-Lok** targets catheter‑related bloodstream infections with a catheter‑salvaging antibiotic lock solution, a differentiated approach highlighted in contemporaneous presentation and corporate materials as a potential first‑in‑class therapy addressing a serious complication in cancer and hemodialysis patients.
• Clear specialty focus with a late‑stage pipeline narrative. Citius positions itself as a **late‑stage / specialty biopharmaceutical** company with a focus on critical care and anti‑infective products, supported by multiple late‑stage assets (Mino-Lok in Phase 3, Halo‑Lido with Phase 2b completed), which provides a portfolio narrative beyond a single program.
• Well‑defined Phase 3 regulatory path for Mino-Lok. The investor‑deck era coincides with detailed public disclosure of the **pivotal Phase 3 Mino-Lok trial design**, including its multi‑center, randomized structure and clinically meaningful endpoints, giving investors a concrete view of the regulatory path.
• Public‑market access with explicit use of proceeds linked to clinical milestones. Citius is a **NASDAQ‑listed** company and uses transparent **follow‑on public offerings**, such as the September 2019 $7.0 million underwritten offering, with clearly stated use of proceeds tied directly to the Mino-Lok Phase 3 trial and other pipeline programs, which helps investors understand capital allocation.
• Established corporate history and public‑company infrastructure. Corporate history and filings affirm a **longstanding corporate structure and governance**, including its origin as a Massachusetts LLC in 2007 and subsequent evolution into a Delaware‑incorporated, Cranford‑based public company, which can reassure investors about organizational stability and regulatory experience.
• High‑credibility academic licensing partner (MD Anderson) for lead asset. Mino-Lok’s development is supported by an exclusive license from **MD Anderson Cancer Center**, an internationally recognized cancer center, which adds external scientific and institutional validation to the program.

What could have been stronger

• Limited financial visibility and cash runway detail in a development‑stage story. The deck is built around Mino-Lok with limited quantitative disclosure, in the public materials around it, of historical financial metrics such as revenue (the company is development‑stage), cash runway, or burn rate, making it harder for investors to assess financing risk and dilution based solely on the deck.
• Sparse commercialization, pricing, and reimbursement discussion for Mino-Lok. While public descriptions emphasize Mino-Lok’s potential to salvage central venous catheters and reduce costs, the materials surrounding the deck give little detail on anticipated pricing, reimbursement pathways, or budget impact modeling, key elements for a hospital‑focused anti‑infective product.
• Pipeline beyond Mino-Lok is mentioned but not equally substantiated. The broader pipeline (e.g., Halo‑Lido, Mino‑Wrap) is referenced in financing disclosures and company descriptions, but the publicly visible deck‑era materials provide far less depth on their differentiation and development plans than on Mino-Lok, limiting the perceived value of portfolio diversification.
• Limited competitive landscape detail for catheter‑related infection management. Given that Citius was already public during this period, the investor story relies heavily on clinical and regulatory milestones, while the available public materials tied to the deck do not clearly benchmark competitive therapies, alternative catheter management practices, or evolving infection‑control standards that could affect market adoption.

How an investor would read this deck

What draws attention

• Validation of Mino-Lok’s mechanism and Phase 2b results in catheter‑related bloodstream infections, and the design and status of the pivotal Phase 3 trial described in presentations and corporate communications.
• How the company plans to translate a first‑in‑class catheter salvage approach into adoption in hospitals and oncology centers, including operational advantages, cost savings, and potential barriers.
• Citius’s ability to finance completion of the Mino-Lok Phase 3 program and advance other assets like Halo‑Lido and Mino‑Wrap, given its reliance on public equity offerings such as the $7.0 million underwritten offering closed in September 2019.
• Regulatory risk and clarity: details of any FDA interactions such as the Phase 3 protocol and later modifications to sample size and endpoints mentioned in corporate updates.

Risks that stand out

• Clinical risk that the pivotal Phase 3 Mino-Lok trial may not replicate the efficacy or safety suggested by Phase 2b data, which would materially impact the company’s value given the asset’s centrality to the story.
• Regulatory risk tied to trial design, endpoint selection, and potential protocol modifications for Mino-Lok, which could affect timing, cost, and probability of approval.
• Financing and dilution risk because Citius is a development‑stage company with no approved products at this time and relies on public equity offerings such as the 2019 $7.0 million underwritten offering to fund operations and clinical trials.
• Commercialization risk that, even with positive Phase 3 data, adoption of a novel catheter salvage therapy may face hurdles in hospital infection‑control protocols, clinician behavior, and reimbursement dynamics.

Questions this deck invites

• What were the full Phase 2b efficacy and safety results for Mino-Lok, and how do these data translate into assumptions for the pivotal Phase 3 trial design and powering?
• How large is the addressable market for catheter‑related bloodstream infections where catheter salvage is clinically and economically preferable to removal, and what is the expected pricing and reimbursement strategy for Mino-Lok in these s
• What is Citius’s cash position and projected runway relative to the anticipated cost and duration of the Mino-Lok Phase 3 trial and the development of Halo‑Lido and Mino‑Wrap, and how dependent is the company on further dilutive equity rais
• What intellectual property and exclusivity protections exist around Mino-Lok (composition, method of use, or formulation), and what is the competitive landscape for catheter‑related infection treatments and catheter salvage technologies?
• How has Citius historically executed on clinical and regulatory timelines, including any delays or modifications (e.g., sample size changes or endpoint adjustments), and what are the updated milestones investors should monitor?

What founders can take from the Citius Pharmaceuticals, Inc. deck

• A development‑stage public biopharmaceutical company can use an investor deck centered on a single late‑stage asset (here, Mino-Lok) to position itself as a focused critical‑care player, provided it clearly connects Phase 2b data to a pivotal Phase 3 strategy and regulatory path.
• Tying a deck directly to concrete financing disclosures (such as a specified public offering intended to fund a Phase 3 trial and other programs) gives investors a clearer view of how new capital will be deployed.
• Highlighting a first‑in‑class mechanism that addresses a costly and morbid complication of standard care—such as catheter‑related bloodstream infections—can differentiate a small company’s lead asset even before commercialization.
• For hospital‑focused anti‑infective products, investors pay close attention not only to clinical endpoints but also to procedural and economic advantages, which the Citius materials emphasize via catheter salvage and potential reduction in infection‑related complications and costs.
• Maintaining consistency between SEC filings, press releases, and investor decks on trial stage, endpoints, and use of proceeds strengthens credibility for a small public biotech raising capital repeatedly on the public markets.
• Using a deck to position additional assets (such as Halo‑Lido and Mino‑Wrap) alongside the lead program can signal a pipeline‑building strategy, but investors will still primarily underwrite the most advanced asset unless equally detailed data are provided.

Citius Pharmaceuticals, Inc. pitch deck: common questions

What does Citius Pharmaceuticals (CTXR) do?

Citius Pharmaceuticals, Inc. (NASDAQ: CTXR) is a late‑stage/specialty biopharmaceutical company focused on developing and commercializing critical care products, particularly anti‑infective therapies and oncology supportive care, including its lead product candidate Mino-Lok for catheter‑related bloodstream infections.

What is the main focus of the Citius CTXR investor deck from 2018–2019?

The deck covers Citius’s strategy and clinical data around **Mino-Lok**, an antibiotic lock solution intended to salvage infected central venous catheters in patients with catheter‑related bloodstream infections, as it moves from Phase 2b data into a pivotal Phase 3 trial under an FDA‑cleared protocol.

What is Mino-Lok and why is it important in this pitch deck?

Mino-Lok is an antibiotic lock solution licensed from MD Anderson Cancer Center that is designed to treat catheter‑related bloodstream infections by salvaging the infected catheter rather than removing and replacing it, thereby potentially reducing infection‑related complications, procedure risks and costs.

What financing was Citius pursuing around the time of this investor deck?

During 2019, Citius raised capital through a $7.0 million underwritten public offering of common stock and warrants, with stated use of proceeds including funding the Phase 3 Mino-Lok clinical trial, the IND pathway for Mino-Wrap, the Phase 2b trial of Halo‑Lido, and general corporate purposes. This type of follow‑on public equity financing is the main capital‑raising context around which this deck would have been used.

When was Citius Pharmaceuticals founded and where is it based?

Citius was originally formed as Citius Pharmaceuticals, LLC in Massachusetts on January 23, 2007, later becoming Citius Pharmaceuticals, Inc. and, by the time of this deck, operating as a NASDAQ‑listed biopharmaceutical company headquartered in Cranford, New Jersey.

Sources

Funding and outcome facts on this page were researched on 2026-08-21 from the pages below.

• Citius Pharmaceuticals Issues Corporate Update
• Untitled-1
• Ctxr presentation mid-size_02.22.2019_spring.final
• Disclaimer This presentation has been prepared by Citius...
• UNITED STATES
• Company Overview - CTXR - NASDAQ - Weiss Ratings
• Citius Announces Closing of $7.0 Million Underwritten Offering Priced At-the-Market
• Citius Pharmaceuticals (CTXR) Company Profile & Description

Related fundraising guides (24)

• Calico Pitch Deck Teardown: A 6-Slide Masterclass in Supply Chain Simplification
• Arize AI Pitch Deck Teardown: A Masterclass in Category Creation and Market Timing
• Hedra Pitch Deck Teardown: A $32M Series A Built on Capital-Efficient AI Research
• Yuzu Health Pitch Deck Teardown: A Masterclass in Market Education and Infrastructure Replacement
• Hone Pitch Deck Teardown: Defining the 'Missing Middle' of Corporate Learning
• Florence Pitch Deck Teardown: Scaling a Healthcare Staffing Marketplace to £9bn Market Potential
• Dame Pitch Deck Teardown: A $7M Series A Masterclass in Normalizing Stigmatized Consumer Goods
• Chptr Pitch Deck Teardown: Modernizing the $120B Death Industry for Digital Natives
• Arkestro Pitch Deck Teardown: A Masterclass in Social Proof and Domain Authority
• 10KC Pitch Deck Teardown: A $56M Growth Round Built on Enterprise Social Proof
• Yelp Pitch Deck Teardown: A Post-IPO Growth Story Focused on Local Ad Dominance
• Hopscotch Pitch Deck Teardown: A $8M Seed Round for Pediatric Behavioral Health Infrastructure
• FX HedgePool Pitch Deck Teardown: Disintermediating the $66 Trillion FX Swap Market
• Domino Data Lab Pitch Deck Teardown: A Masterclass in Enterprise Social Proof
• Cellarity Pitch Deck Teardown: A $121M Series C Masterclass in Platform-First Biotech
• Assembly Pitch Deck Teardown: A Product-First Series A Narrative Focused on Retention
• Aeris Health Pitch Deck Teardown: A Masterclass in Hardware Traction and COVID-Era Pivoting
• Trash Warrior Pitch Deck Teardown: Disrupting the $56B Commercial Waste Collection Market
• Hourly Pitch Deck Teardown: Connecting Payroll Data to Real-Time Workers' Comp Premiums
• Goldcast Pitch Deck Teardown: Turning Virtual Events Into A High-Velocity B2B Revenue Engine
• Depict.ai Pitch Deck Teardown: A Masterclass in Traction-First Seed Fundraising
• Chattermill Pitch Deck Teardown: A Masterclass in Enterprise Social Proof and Expansion Strategy
• authID.ai Pitch Deck Teardown: A Post-IPO Roadmap for Biometric Identity Verification
• Aceiss Pitch Deck Teardown: A Masterclass in Team Credibility and Problem Framing

Decks from the same year (1)

• 2018 pitch deck examples

Decks from the same region (1)

• US pitch deck examples

Browse companies alphabetically (1)

• Pitch decks from companies starting with C

More pitch deck teardowns (16)

• Circe Pitch Deck Breakdown: A Deep Dive into Methane-to-Protein Industrial Biotech
• Circle Internet Pitch Deck Breakdown: Scaling the Global Internet of Value via SPAC
• Circles Pitch Deck Teardown: A $16.5M Series A Bet on Scalable Peer Support
• Circ Pitch Deck Teardown: Solving the Polycotton Recycling Gap with Hydrothermal Tech
• Circular Pitch Deck Breakdown: Scaling Cooperative Recruitment via Network Effects
• Circulate Pitch Deck Breakdown: A Deck Named 'investordeck' With No Ask, No Product And No Market Size
• Ciroos Pitch Deck Teardown: A $21M Seed Round Built on Deep Domain Expertise
• Cirrus Identity Pitch Deck Breakdown: A Masterclass in High-Signal, Low-Noise Traction
• Citylitics Pitch Deck Breakdown: Mapping the $2.1T Infrastructure Data Opportunity
• CityScale Pitch Deck Teardown: A Data-Driven Approach to Post-War Housing and Urban Planning
• Civicrowd Pitch Deck Teardown: A Solo-Founder Play for European Civic Crowdfunding
• Claap Pitch Deck Teardown: How a Pre-Product Team Raised $3M on Asynchronous Workflow
• Claap Pitch Deck Breakdown: Defining the Asynchronous Meeting Category
• Cladwell Pitch Deck Breakdown: A Minimalist Approach to Scaling Sustainable Fashion Tech
• ClaimCompass Pitch Deck Breakdown: A Masterclass in High-Signal, Low-Noise Seed Fundraising
• Claira Pitch Deck Teardown: Solving the Legal Logic Gap in Financial Contracts

Recently published pitch deck teardowns (12)

• Paleo Pitch Deck Teardown: A 10-Slide Masterclass in Scientific Differentiation
• Papercup Pitch Deck Teardown: How AI-Powered Dubbing Raised a $20M Series A
• Parafin Pitch Deck Teardown: A Masterclass in Embedded Credit Infrastructure Strategy
• Pave Pitch Deck Teardown: A Masterclass in Data Flywheels and Explosive SaaS Growth
• Patient21 Pitch Deck Teardown: Scaling a Digi-Physical Healthcare Ecosystem in Europe
• Patchwork Health Pitch Deck Teardown: A Category-Creation Play for Healthcare Workforce SaaS
• Pebble Pitch Deck Teardown: A $6.2M Seed Round Built on Anti-Banking Sentiment
• PilotDesk Pitch Deck Teardown: A Lean $3M Seed Deck Focused on Ad-Ops Automation
• PlanetWatchers Pitch Deck Teardown: A Data-Driven Approach to Crop Insurance and Sustainability
• Podimetrics Pitch Deck Teardown: A Masterclass in Clinical Validation and Payor ROI
• Portkey.ai Pitch Deck Teardown: A Developer-First Approach to the LLMOps Infrastructure Layer
• Postmoda Pitch Deck Teardown: A Masterclass in Social Proof and Traction-First Storytelling

Fundraising library · Pitch deck examples · Investor directory · Founder database